MED19

Across TCGA pan-cancer cohorts, MED19 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MED19 data layer compared with 28 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MED19 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MED19 expression acts as an unfavorable survival marker.

BLCA and ESCA are the cancer types where MED19 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.130	0.599	.002	12	view →
ESCA	OS	Median	II,III,IV	0.226	0.686	.023	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

MED19–BLCA (OS)

Open the BLCA breakdown →